HEPATIC SAFETY OF OZANIMOD IN ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS PHASE 3 TRIALS

David T. Rubin  ¹     Freddy Caldera  ²     Jeffrey Cohen  ³     Stefan Zeuzem  ⁴     Chun-Yen Cheng  ⁵     Shabana Ather  ⁵     Lorna Charles  ⁵     James K. Sheffield  ⁵     Axel Dignass  ^6    
1 University of Chicago Medicine Inflammatory Bowel Disease, Chicago, United States
² University of Wisconsin School of Medicine and Public Health, Madison, United States
³ Cleveland Clinic, Cleveland, United States
⁴ Goethe University Hospital, Frankfurt, Germany
⁵ Bristol Myers Squibb, Princeton, United States
⁶ Agaplesion Markus Hospital, Goethe University, Frankfurt, Germany

Session
Safety and emergencies in lower GI disease (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)